Limits...
The comparison of surgical patients with primary hepatic squamous cell carcinoma or adenosquamous carcinoma and surgical patients with hepatocellular carcinoma.

Yan L, Xie F, Yang C, Yu L, Zheng T, Fu J, Yang J - World J Surg Oncol (2015)

Bottom Line: Serum tumor markers showed significant differences between primary hepatic SCC/ASC and HCC patients, especially for serum alpha fetal protein (AFP) level and carbohydrate antigen 19-9 (CA 19-9).Significant difference was not discovered when SCC and ASC patients were compared with HCC patients (P = 0.294).And the treatment of liver resection was effective for those patients who met the selection criteria for liver resection.

View Article: PubMed Central - PubMed

Affiliation: Department of Special Treatment and Liver Transplantation, Eastern Hepatobiliary Hospital, the Second Military Medical University, 255 Changhai Road, Shanghai, 200438, China. hunanxiefeng@yahoo.com.cn.

ABSTRACT

Background: There are still several controversies and ambiguities in the aspects of primary hepatic squamous cell carcinoma and primary hepatic adenosquamous carcinoma. To further clarify the specific features of these two infrequent diseases and provide beneficial propose for clinical decision, we did this retrospective study.

Methods: We reviewed the clinical features and outcomes of three primary hepatic squamous cell carcinoma (SCC) patients and six primary hepatic adenosquamous carcinoma (ASC) patients from January 1998 to December 2011 in Eastern Hepatobiliary Surgery Hospital in China. Meanwhile, 40 hepatocellular carcinoma (HCC) patients and 26 metastatic hepatic SCC or ASC patients who were hospitalized in the same period were also reviewed to make a comparison. In order to find out the definite survival information of SCC and ASC patients, 30 previous studies containing 37 primary hepatic SCC (16) and ASC (21) patients were reviewed, and their information of survival was analyzed together with the included patients in our hospital.

Results: Serum tumor markers showed significant differences between primary hepatic SCC/ASC and HCC patients, especially for serum alpha fetal protein (AFP) level and carbohydrate antigen 19-9 (CA 19-9). On the pathologic performance, primary SCC/ASC tumor was rarely accompanied with tumor capsule. They presented peripheral hepatic lymph node metastasis more likely and showed low proportion of microvascular invasion. The median survival time of primary hepatic SCC/ASC patients after liver resection (LR) was 15 months. And the 1-, 3-, 5-year survival rates after LR were 60%, 24%, and 12%, respectively. Significant difference was not discovered when SCC and ASC patients were compared with HCC patients (P = 0.294). The median survival time after LR for primary SCC and ASC patients was respectively 23 months and 13 months.

Conclusions: The comprehensive application of some clinical characteristics, histopathologic features, and imaging findings may be useful for us in making definite diagnoses for primary hepatic SCC and ASC patients preoperatively. And the treatment of liver resection was effective for those patients who met the selection criteria for liver resection.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier cumulative survival curves of the two groups of patients for overall survival(OS).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4358902&req=5

Fig2: Kaplan-Meier cumulative survival curves of the two groups of patients for overall survival(OS).

Mentions: As mentioned above, because the survival of the metastatic hepatic SCC and ASC patients might be significantly affected by the primary tumor disease, it was insufficient to analyze the survival just basing on the metastatic hepatic tumor diseases. So the survival analysis was only conducted in primary SCC/ASC and HCC patients (total 49 patients). The median time of follow-up was 20 months, arranged from 4 to 72 months. Till the end of follow-up period, there was only one patient alive in the primary SCC/ASC group. The median time of survival for these nine patients after LR was 15 months, and the mean of survival time was 19.778 ± 4.389 months. Primary SCC/ASC patients’ 1-, 3-, 5-year survival rates after LR were 67%, 20%, and 0%. For the 40 included HCC patients in this study, the median survival time after LR was 23 months and the mean of survival time was 29.405 ± 3.614 months. We also found their 1-, 3-, 5-year survival rates after LR were 68%, 35%, and 14%. The short-term survival after LR of these two groups of patients was nearly the same, but the long-term survival of the HCC patients seemed better than that of the primary SCC/ASC patients. However, we found no significant difference of the overall survival between two groups of patients (log rank χ2 = 1.216, P = 0.27, Figure 2).Figure 2


The comparison of surgical patients with primary hepatic squamous cell carcinoma or adenosquamous carcinoma and surgical patients with hepatocellular carcinoma.

Yan L, Xie F, Yang C, Yu L, Zheng T, Fu J, Yang J - World J Surg Oncol (2015)

Kaplan-Meier cumulative survival curves of the two groups of patients for overall survival(OS).
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4358902&req=5

Fig2: Kaplan-Meier cumulative survival curves of the two groups of patients for overall survival(OS).
Mentions: As mentioned above, because the survival of the metastatic hepatic SCC and ASC patients might be significantly affected by the primary tumor disease, it was insufficient to analyze the survival just basing on the metastatic hepatic tumor diseases. So the survival analysis was only conducted in primary SCC/ASC and HCC patients (total 49 patients). The median time of follow-up was 20 months, arranged from 4 to 72 months. Till the end of follow-up period, there was only one patient alive in the primary SCC/ASC group. The median time of survival for these nine patients after LR was 15 months, and the mean of survival time was 19.778 ± 4.389 months. Primary SCC/ASC patients’ 1-, 3-, 5-year survival rates after LR were 67%, 20%, and 0%. For the 40 included HCC patients in this study, the median survival time after LR was 23 months and the mean of survival time was 29.405 ± 3.614 months. We also found their 1-, 3-, 5-year survival rates after LR were 68%, 35%, and 14%. The short-term survival after LR of these two groups of patients was nearly the same, but the long-term survival of the HCC patients seemed better than that of the primary SCC/ASC patients. However, we found no significant difference of the overall survival between two groups of patients (log rank χ2 = 1.216, P = 0.27, Figure 2).Figure 2

Bottom Line: Serum tumor markers showed significant differences between primary hepatic SCC/ASC and HCC patients, especially for serum alpha fetal protein (AFP) level and carbohydrate antigen 19-9 (CA 19-9).Significant difference was not discovered when SCC and ASC patients were compared with HCC patients (P = 0.294).And the treatment of liver resection was effective for those patients who met the selection criteria for liver resection.

View Article: PubMed Central - PubMed

Affiliation: Department of Special Treatment and Liver Transplantation, Eastern Hepatobiliary Hospital, the Second Military Medical University, 255 Changhai Road, Shanghai, 200438, China. hunanxiefeng@yahoo.com.cn.

ABSTRACT

Background: There are still several controversies and ambiguities in the aspects of primary hepatic squamous cell carcinoma and primary hepatic adenosquamous carcinoma. To further clarify the specific features of these two infrequent diseases and provide beneficial propose for clinical decision, we did this retrospective study.

Methods: We reviewed the clinical features and outcomes of three primary hepatic squamous cell carcinoma (SCC) patients and six primary hepatic adenosquamous carcinoma (ASC) patients from January 1998 to December 2011 in Eastern Hepatobiliary Surgery Hospital in China. Meanwhile, 40 hepatocellular carcinoma (HCC) patients and 26 metastatic hepatic SCC or ASC patients who were hospitalized in the same period were also reviewed to make a comparison. In order to find out the definite survival information of SCC and ASC patients, 30 previous studies containing 37 primary hepatic SCC (16) and ASC (21) patients were reviewed, and their information of survival was analyzed together with the included patients in our hospital.

Results: Serum tumor markers showed significant differences between primary hepatic SCC/ASC and HCC patients, especially for serum alpha fetal protein (AFP) level and carbohydrate antigen 19-9 (CA 19-9). On the pathologic performance, primary SCC/ASC tumor was rarely accompanied with tumor capsule. They presented peripheral hepatic lymph node metastasis more likely and showed low proportion of microvascular invasion. The median survival time of primary hepatic SCC/ASC patients after liver resection (LR) was 15 months. And the 1-, 3-, 5-year survival rates after LR were 60%, 24%, and 12%, respectively. Significant difference was not discovered when SCC and ASC patients were compared with HCC patients (P = 0.294). The median survival time after LR for primary SCC and ASC patients was respectively 23 months and 13 months.

Conclusions: The comprehensive application of some clinical characteristics, histopathologic features, and imaging findings may be useful for us in making definite diagnoses for primary hepatic SCC and ASC patients preoperatively. And the treatment of liver resection was effective for those patients who met the selection criteria for liver resection.

No MeSH data available.


Related in: MedlinePlus